GSK Stock Overview
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£17.86|
|52 Week High||UK£27.27|
|52 Week Low||UK£13.63|
|1 Month Change||4.56%|
|3 Month Change||8.04%|
|1 Year Change||24.19%|
|3 Year Change||9.10%|
|5 Year Change||10.60%|
|Change since IPO||-4.87%|
Recent News & Updates
|GSK||GB Pharmaceuticals||GB Market|
Return vs Industry: GSK exceeded the UK Pharmaceuticals industry which returned 18.7% over the past year.
Return vs Market: GSK exceeded the UK Market which returned -9.7% over the past year.
|GSK Average Weekly Movement||2.9%|
|Pharmaceuticals Industry Average Movement||5.4%|
|Market Average Movement||5.4%|
|10% most volatile stocks in GB Market||10.6%|
|10% least volatile stocks in GB Market||2.8%|
Stable Share Price: GSK is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: GSK's weekly volatility (3%) has been stable over the past year.
About the Company
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology.
GSK Fundamentals Summary
|GSK fundamental statistics|
Is GSK overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GSK income statement (TTM)|
|Cost of Revenue||UK£12.66b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Jul 27, 2022
|Earnings per share (EPS)||1.01|
|Net Profit Margin||14.02%|
How did GSK perform over the long term?See historical performance and comparison
4.5%Current Dividend Yield
Is GSK undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GSK?
Other financial metrics that can be useful for relative valuation.
|What is GSK's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does GSK's PE Ratio compare to its peers?
|GSK PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: GSK is expensive based on its Price-To-Earnings Ratio (17.7x) compared to the peer average (17x).
Price to Earnings Ratio vs Industry
How does GSK's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Earnings vs Industry: GSK is expensive based on its Price-To-Earnings Ratio (17.7x) compared to the UK Pharmaceuticals industry average (16.5x)
Price to Earnings Ratio vs Fair Ratio
What is GSK's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||17.7x|
|Fair PE Ratio||46.6x|
Price-To-Earnings vs Fair Ratio: GSK is good value based on its Price-To-Earnings Ratio (17.7x) compared to the estimated Fair Price-To-Earnings Ratio (46.6x).
Share Price vs Fair Value
What is the Fair Price of GSK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: GSK (£17.86) is trading below our estimate of fair value (£47.58)
Significantly Below Fair Value: GSK is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: GSK is poor value based on its PEG Ratio (1.7x)
Discover undervalued companies
How is GSK forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GSK's forecast earnings growth (10.4% per year) is above the savings rate (0.9%).
Earnings vs Market: GSK's earnings (10.4% per year) are forecast to grow slower than the UK market (11% per year).
High Growth Earnings: GSK's earnings are forecast to grow, but not significantly.
Revenue vs Market: GSK's revenue (4.6% per year) is forecast to grow faster than the UK market (4.2% per year).
High Growth Revenue: GSK's revenue (4.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GSK's Return on Equity is forecast to be high in 3 years time (33%)
Discover growth companies
How has GSK performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GSK has high quality earnings.
Growing Profit Margin: GSK's current net profit margins (14%) are lower than last year (16.2%).
Past Earnings Growth Analysis
Earnings Trend: GSK's earnings have grown significantly by 22.7% per year over the past 5 years.
Accelerating Growth: GSK's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: GSK had negative earnings growth (-2.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (2.2%).
Return on Equity
High ROE: Whilst GSK's Return on Equity (26.52%) is high, this metric is skewed due to their high level of debt.
Discover strong past performing companies
How is GSK's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: GSK's short term assets (£29.0B) exceed its short term liabilities (£24.3B).
Long Term Liabilities: GSK's short term assets (£29.0B) do not cover its long term liabilities (£42.8B).
Debt to Equity History and Analysis
Debt Level: GSK's net debt to equity ratio (85.6%) is considered high.
Reducing Debt: GSK's debt to equity ratio has reduced from 327.6% to 147.4% over the past 5 years.
Debt Coverage: GSK's debt is well covered by operating cash flow (30.5%).
Interest Coverage: GSK's interest payments on its debt are well covered by EBIT (11.2x coverage).
Discover healthy companies
What is GSK current dividend yield, its reliability and sustainability?
Dividend Score 5/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: GSK's dividend (4.48%) is higher than the bottom 25% of dividend payers in the UK market (1.89%).
High Dividend: GSK's dividend (4.48%) is low compared to the top 25% of dividend payers in the UK market (5.29%).
Stability and Growth of Payments
Stable Dividend: GSK's dividends per share have been stable in the past 10 years.
Growing Dividend: GSK's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (73.5%), GSK's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (54.4%), GSK's dividend payments are covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Emma Walmsley (52 yo)
Dame Emma N. Walmsley serves as an Independent Director of Microsoft Corp. since December 4, 2019. She serves as Chief Executive Officer of GlaxoSmithKline Plc since April 1, 2017. Dame Walmsley served as...
CEO Compensation Analysis
Compensation vs Market: Emma's total compensation ($USD9.87M) is above average for companies of similar size in the UK market ($USD5.27M).
Compensation vs Earnings: Emma's compensation has been consistent with company performance over the past year.
Experienced Management: GSK's management team is considered experienced (4.3 years average tenure).
Experienced Board: GSK's board of directors are considered experienced (5.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
GSK plc's employee growth, exchange listings and data sources
- Name: GSK plc
- Ticker: GSK
- Exchange: LSE
- Founded: 1715
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: UK£90.358b
- Shares outstanding: 5.06b
- Website: https://www.gsk.com
Number of Employees
- GSK plc
- 980 Great West Road
- Greater London
- TW8 9GS
- United Kingdom
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/03 00:00|
|End of Day Share Price||2022/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.